Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Metrics to compare | CLNN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLNNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −3.0x | −0.6x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | −81.0x | 3.1x | 2.6x | |
Price / LTM Sales | 92.4x | 21.6x | 3.2x | |
Upside (Analyst Target) | - | 240.2% | 46.5% | |
Fair Value Upside | Unlock | 17.7% | 6.6% | Unlock |